Citius Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Citius Pharmaceuticals, Inc. (CTXR) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $214.25 thousand for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-12-23
- Citius Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $62.04K, a 15.56% increase year-over-year.
- Citius Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $41.37K, a 21.32% decline year-over-year.
- Citius Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $56.01K, a 8.78% increase year-over-year.
- Citius Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $54.84K, a 8.73% increase year-over-year.
- Citius Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $214.25K, a 2.92% increase from fiscal 2024.
- Citius Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $208.18K, a 8.63% increase from fiscal 2023.
- Citius Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $191.65K, a 8.43% increase from fiscal 2022.
- Citius Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $176.75K, a 8.19% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $62.04K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $103.41K derived: sum of 2 quarters · filed 2025-12-23 | $159.41K derived: sum of 3 quarters · filed 2025-12-23 | $214.25K 10-K · filed 2025-12-23 |
| 2025-06-30 | $41.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $97.38K derived: sum of 2 quarters · filed 2025-08-12 | $152.21K 10-Q · filed 2025-08-12 | $205.90K derived: sum of 4 quarters · filed 2025-12-23 |
| 2025-03-31 | $56.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | $110.84K 10-Q · filed 2025-05-14 | $164.53K derived: sum of 3 quarters · filed 2025-12-23 | $217.10K derived: sum of 4 quarters · filed 2025-12-23 |
| 2024-12-31 | $54.84K 10-Q · filed 2025-02-14 | $108.52K derived: sum of 2 quarters · filed 2025-12-23 | $161.09K derived: sum of 3 quarters · filed 2025-12-23 | $212.58K derived: sum of 4 quarters · filed 2025-12-23 |
| 2024-09-30 | $53.69K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $106.26K derived: sum of 2 quarters · filed 2025-12-23 | $157.75K derived: sum of 3 quarters · filed 2025-12-23 | $208.18K 10-K · filed 2025-12-23 |
| 2024-06-30 | $52.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $104.06K derived: sum of 2 quarters · filed 2025-08-12 | $154.49K 10-Q · filed 2025-08-12 | $203.88K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $51.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | $101.92K 10-Q · filed 2025-05-14 | $151.31K derived: sum of 3 quarters · filed 2025-05-14 | $199.70K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $50.43K 10-Q · filed 2025-02-14 | $99.82K derived: sum of 2 quarters · filed 2025-02-14 | $148.21K derived: sum of 3 quarters · filed 2025-02-14 | $195.62K derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $49.39K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | $97.78K derived: sum of 2 quarters · filed 2024-12-27 | $145.19K derived: sum of 3 quarters · filed 2024-12-27 | $191.65K 10-K · filed 2024-12-27 |
| 2023-06-30 | $48.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-12 | $95.80K derived: sum of 2 quarters · filed 2024-08-12 | $142.26K 10-Q · filed 2024-08-12 | $187.78K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $47.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-14 | $93.87K 10-Q · filed 2024-05-14 | $139.39K derived: sum of 3 quarters · filed 2024-05-14 | $184.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $46.46K 10-Q · filed 2024-02-14 | $91.98K derived: sum of 2 quarters · filed 2024-02-14 | $136.59K derived: sum of 3 quarters · filed 2024-02-14 | $180.33K derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-09-30 | $45.52K derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-29 | $90.14K derived: sum of 2 quarters · filed 2023-12-29 | $133.88K derived: sum of 3 quarters · filed 2023-12-29 | $176.75K 10-K · filed 2023-12-29 |
| 2022-06-30 | $44.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-14 | $88.36K derived: sum of 2 quarters · filed 2023-08-14 | $131.24K 10-Q · filed 2023-08-14 | $173.27K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $43.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12 | $86.62K 10-Q · filed 2023-05-12 | $128.66K derived: sum of 3 quarters · filed 2023-05-12 | $169.88K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $42.88K 10-Q · filed 2023-02-10 | $84.92K derived: sum of 2 quarters · filed 2023-02-10 | $126.14K derived: sum of 3 quarters · filed 2023-02-10 | |
| 2021-09-30 | $42.04K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-22 | $83.26K derived: sum of 2 quarters · filed 2022-12-22 | $163.38K 10-K · filed 2022-12-22 | |
| 2021-06-30 | $41.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-11 | $121.34K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $80.11K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |